Calithera Biosciences, Inc. (CALA) Expected to Post Earnings of -$0.25 Per Share
Equities research analysts predict that Calithera Biosciences, Inc. (NASDAQ:CALA) will post ($0.25) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Calithera Biosciences’ earnings, with the lowest EPS estimate coming in at ($0.30) and the highest estimate coming in at ($0.17). Calithera Biosciences reported earnings of ($0.44) per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 43.2%. The business is scheduled to announce its next quarterly earnings report on Wednesday, November 8th.
According to Zacks, analysts expect that Calithera Biosciences will report full-year earnings of ($0.88) per share for the current fiscal year, with EPS estimates ranging from ($0.96) to ($0.73). For the next financial year, analysts anticipate that the business will post earnings of ($0.80) per share, with EPS estimates ranging from ($0.98) to ($0.45). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research analysts that follow Calithera Biosciences.
Calithera Biosciences (NASDAQ:CALA) last issued its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.14. The company had revenue of $7.26 million during the quarter, compared to analyst estimates of $4.80 million.
Several equities analysts recently commented on the stock. William Blair assumed coverage on shares of Calithera Biosciences in a research note on Thursday, October 5th. They issued an “outperform” rating for the company. BidaskClub raised shares of Calithera Biosciences from a “strong sell” rating to a “sell” rating in a research note on Friday, August 18th. Finally, Zacks Investment Research downgraded shares of Calithera Biosciences from a “buy” rating to a “hold” rating in a research note on Thursday, July 13th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $15.50.
TRADEMARK VIOLATION WARNING: “Calithera Biosciences, Inc. (CALA) Expected to Post Earnings of -$0.25 Per Share” was originally reported by American Banking News and is the property of of American Banking News. If you are reading this story on another site, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/10/17/calithera-biosciences-inc-cala-expected-to-post-earnings-of-0-25-per-share.html.
Shares of Calithera Biosciences (CALA) traded up 2.31% during mid-day trading on Tuesday, hitting $17.75. 476,897 shares of the company were exchanged. The company’s 50-day moving average price is $16.15 and its 200-day moving average price is $14.69. The firm’s market capitalization is $629.70 million. Calithera Biosciences has a 12-month low of $2.20 and a 12-month high of $20.05.
In other news, major shareholder Adage Capital Partners Gp, L.L sold 576,000 shares of the firm’s stock in a transaction on Thursday, September 28th. The shares were sold at an average price of $15.64, for a total transaction of $9,008,640.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 16.30% of the stock is currently owned by company insiders.
Several hedge funds have recently added to or reduced their stakes in CALA. Nationwide Fund Advisors bought a new position in shares of Calithera Biosciences during the first quarter valued at $131,000. Bank of New York Mellon Corp raised its stake in shares of Calithera Biosciences by 17.5% during the first quarter. Bank of New York Mellon Corp now owns 32,688 shares of the biotechnology company’s stock valued at $377,000 after acquiring an additional 4,863 shares during the last quarter. Raymond James Financial Services Advisors Inc. bought a new position in shares of Calithera Biosciences during the first quarter valued at $117,000. SG Americas Securities LLC bought a new position in shares of Calithera Biosciences during the first quarter valued at $211,000. Finally, Victory Capital Management Inc. bought a new position in shares of Calithera Biosciences during the first quarter valued at $1,168,000. 71.88% of the stock is owned by hedge funds and other institutional investors.
Calithera Biosciences Company Profile
Calithera Biosciences, Inc is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Calithera Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.